<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ATOMOXETINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ATOMOXETINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Attention deficit hyperactivity disorder (initiated by a specialist)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 70 kg)</strong><br/>
                Initially 500 micrograms/kg daily for 7 days, dose is increased according to response; maintenance 1.2 mg/kg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 1.8 mg/kg per day; maximum 120 mg per day.</li>
              <li class="dose adult"><strong>For adults (body-weight 70 kg and above)</strong><br/>
                Initially 40 mg daily for 7 days, dose is increased according to response; maintenance 80&#8211;100 mg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 120 mg per day.</li>
              <li class="dose child"><strong>For children 6&#8211;17 years (body-weight 70 kg and above)</strong><br/>
                Initially 40 mg daily for 7 days, dose is increased according to response; maintenance 80 mg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 120 mg per day.</li>
              <li class="dose child"><strong>For children 6&#8211;17 years (body-weight up to 70 kg)</strong><br/>
                Initially 500 micrograms/kg daily for 7 days, dose is increased according to response; maintenance 1.2 mg/kg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 1.8 mg/kg per day; maximum 120 mg per day.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Halve dose in moderate impairment.</p><p>Quarter dose in severe impairment.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Phaeochromocytoma</li>
            <li>severe cardiovascular disease</li>
            <li>severe cerebrovascular disease</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, anorexia, anxiety, constipation, depression, dermatitis, dizziness, drowsiness, dry mouth, dyspepsia, flatulence, flushing, headache, hills, increased blood pressure, irritability, lethargy, malaise, mydriasis, nausea, palpitation, paraesthesia, prostatitis, rash, sexual dysfunction, sleep disturbances, sweating, tachycardia, taste disturbances, tremor, urinary dysfunction, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Aggression, cold extremities, emotional lability, hostility, hypoaesthesia, menstrual disturbances, muscle spasms, pruritus, psychosis, QT-interval prolongation, suicidal ideation, syncope, tics,
              </p>
              <p>
                <strong>rare:</strong> Raynaud&#8217;s phenomenon, seizures,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma, hepatic disorders,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Suicidal ideation</h3>
              <p>Following reports of suicidal thoughts and behaviour, patients and their carers should be informed about the risk and told to report clinical worsening, suicidal thoughts or behaviour, irritability, agitation, or depression.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Hepatic impairment</h3>
              <p>Following rare reports of hepatic disorders, patients and carers should be advised of the risk and be told how to recognise symptoms; prompt medical attention should be sought in case of abdominal pain, unexplained nausea, malaise, darkening of the urine, or jaundice.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Atomoxetine for attention deficit hyperactivity disorder (ADHD)</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/atomoxetine-attention-deficit-hyperactivity-disorder-adhd">www.medicinesforchildren.org.uk/atomoxetine-attention-deficit-hyperactivity-disorder-adhd</xref>
            </p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA98</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) (March 2006)</p> <p>Atomoxetine is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents.</p><xref format="html" href="http://www.nice.org.uk/TA98">www.nice.org.uk/TA98</xref>
                <a href="http://www.nice.org.uk/TA98" target="_blank">www.nice.org.uk/TA98</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            QT-interval prolongation
          </li>
          <li>
            aggressive behaviour
          </li>
          <li>
            cardiovascular disease
          </li>
          <li>
            cerebrovascular disease
          </li>
          <li>
            emotional lability
          </li>
          <li>
            history of seizures
          </li>
          <li>
            hostility
          </li>
          <li>
            hypertension
          </li>
          <li>
            mania
          </li>
          <li>
            psychosis
          </li>
          <li>
            structural cardiac abnormalities
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
          <li>
            tachycardia
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Doses above 100&#8239;mg daily is not licensed.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Dose maximum of 120&#8239;mg is not licensed.</p>
            </section>
            <section class="unlicensedUse">
              <p>Atomoxetine doses in BNF may differ from those in product literature.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ATOMOXETINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP77772"><a href="../medicinalForm/PHP77772.html" data-target="#PHP77772" data-action="load">Capsule</a></div>
            <div id="PHP77776"><a href="../medicinalForm/PHP77776.html" data-target="#PHP77776" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
